Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Rituximab combined with a specific intensive chemotherapy is considered the standard
treatment for newly diagnosed patients with mature B leukemia/lymphoma. However, the toxicity
of this therapy is high. The purpose of this trial is to reduce the dose intensity of the
chemotherapy blocks once the patient has achieved complete response. With this approach the
investigators expect to maintain the efficacy and to reduce the toxicity of the chemotherapy,
specially the rate of deaths in complete response.
Phase:
Phase 2
Details
Lead Sponsor:
PETHEMA Foundation
Collaborator:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea